Analyst consensus rating
Prelude Therapeutics Analyst Rating: Strong Buy
PRLD is rated Strong Buy by 3 analysts with a $8.00 target. As of 2026-08-21.
Direct answer
Prelude Therapeutics's consensus rating is Strong Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $8.00.
Forecast evidence checked August 21, 2026.
Get free Prelude Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $6.50
- Average price target
- $8.00
- High price target
- $10.00
- Low price target
- $6.00
- Low target gap
- -7.7%
- Target upside
- +23.1%
- High target gap
- +53.8%
- Target range width
- 61.5%
- Consensus rating
- Strong Buy
- Analysts
- 3
- Evidence date
- August 21, 2026
- Valid through
- August 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Prelude Therapeutics?
Prelude Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $8.00.
How far are Prelude Therapeutics's low and high targets from the recorded price?
The low target implies -7.7%, while the high target implies +53.8%.
How many analysts are included in Prelude Therapeutics's consensus?
The verified consensus includes 3 analysts.
How is Prelude Therapeutics's target upside or downside calculated?
The average target of $8.00 is divided by the recorded price of $6.50, then one is subtracted to produce +23.1%. This does not guarantee a future return.
When was Prelude Therapeutics's analyst forecast verified?
The data was verified on 2026-08-21. The dataset is valid through 2026-08-28.